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Abstract
Purpose Erythropoiesis-stimulating agents can reduce red
blood cell transfusion rates in patients developing anemia
while receiving chemotherapy. We investigated potential
cost savings from reduced transfusion rates in patients starting
darbepoetin alfa (DA) at higher versus lower hemoglobin
(Hb) levels.
Methods Two systematic literature reviews were performed:
transfusion outcomes in patients receiving DA stratified by
baseline Hb level and costs of transfusion in Europe. Poten-
tial cost savings were calculated by multiplying the differ-
ence in transfusion rates between Hb levels by the midpoint
of transfusion costs.
Results Despite differences in baseline characteristics, treat-
ment duration and analysis technique, the clinical studies
(n08) showed that fewer transfusions were required when
DA was initiated at higher versus lower Hb levels. The
economic studies (n09) showed that 1 unit of transfusion
ranged from €130 to €537 (2010-adjusted values). Cost
savings from initiating DA at higher versus lower Hb levels
were €503–2,226 (2 units transfused) and €880–3,895
(3.5 units) per ten patients.
Conclusions Transfusion incidence increases with DA initi-
ation at lower Hb levels. Potential cost savings depend on
the number of units transfused and cost items included. DA
initiation according to guidelines can reduce transfusions
and potentially reduce transfusion-associated costs.
Keywords Costs . Darbepoetin alfa . Erythropoiesis-
stimulating agents . Hemoglobin . Transfusion
Introduction
Chemotherapy is a frequent cause of anemia in patients with
cancer [1]. In this population, anemia increases the risk of
death [2], and is also associated with impaired quality of life
[3, 4]. Until the early 1980s, red blood cell (RBC) trans-
fusions were the primary treatment for chemotherapy-
induced anemia [5]. This changed in 1993 when the use of
erythropoiesis-stimulating agents (ESAs) was approved by
the US Food and Drug Administration for the treatment of
anemia in patients with cancer. Approval of ESAs in Europe
by the European Medicines Agency followed in 2001. No-
tably, ESA treatment of chemotherapy-induced anemia can
reduce the requirements for RBC transfusions [6], which are
associated with various risks including enhanced tumor
growth, transmission of infectious diseases, and adverse
reactions [1].
The goal of the treatment is improving fatigue symptoms
by correcting anemia. According to current guidelines from
the European Organisation for Research and Treatment of
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Cancer, ESA treatment should be initiated at a hemoglobin
(Hb) level of 9–11 g/dl in patients experiencing anemia-
related symptoms while receiving systemic chemotherapy
[6]. The European Society for Medical Oncology (ESMO)
acknowledges the importance of anemia in cancer, through
the negative impact upon the quality of life and as a negative
prognosis factor regarding general survival [7]. ESMO rec-
ommends ESA use in the treatment of the symptomatic
anemia induced by chemotherapy of adult patients with
nonmyeloid malignancies with Hb values ≤10 g/dl. The goal
of the treatment is improving the fatigue symptoms by
correcting anemia. ASCO/ASH recommends use of ESA
when Hb levels are ≤10 g/dL while considering other clin-
ical circumstances [8]. Similarly, the European Summaries
of Product Characteristics for ESAs state that treatment
should be initiated when the Hb level falls to ≤10 g/dl
[9–11]. In contrast, based on recent RBC transfusion guide-
lines [12], the recommended hemoglobin trigger for trans-
fusion should be 7 g/dL in stable, non-bleeding patients.
Importantly, the Hb level at the time of ESA initiation
may affect clinical outcomes, including RBC transfusion
rates. For example, a retrospective analysis of a darbepoetin
alfa (DA) study showed that the incidence of RBC transfu-
sion was 31 % when treatment was initiated at Hb levels
<10 g/dl compared with 15 % when treatment was initiated
at Hb levels >10 g/dl [13]. This in turn may affect the costs
of treating chemotherapy-induced anemia.
The aims of the present retrospective study were to
investigate the impact of Hb level at the start of ESA
treatment on the rate of RBC transfusion and to identify
the potential cost-saving benefit of a reduction in trans-
fusion rates, based on a systematic review of the liter-
ature. The present study focuses on DA, an injectable,
long-acting erythropoietin with increased erythropoietin-
stimulating activity relative to epoetin [14]. DA can be
dosed as infrequently as once every 3 weeks, which
allows treatment to be synchronized with many chemo-
therapy schedules [15].
Design and methods
Systematic literature review of relevant clinical studies
A systematic literature review was performed to identify
articles that reported RBC transfusion rates stratified by
Hb level at the time of DA initiation in patients with
chemotherapy-induced anemia. To capture studies that
would be in line with the most recent treatment guidelines
[6], a search was conducted using the PubMed database for
studies published between January 2006 and November
2010. Iterative searches were also conducted of several con-
ference abstract databases [American Society for Clinical
Oncology, American Society for Hematology, European So-
ciety for Medical Oncology (ESMO), ESMO/European Can-
cer Organisation and European Haematology Association
joint congress] for relevant abstracts presented between 2006
and 2010. The search terms were (“darbepoetin alfa” or
“darbepoetin alpha”) and (“chemotherapy-induced ane-
mia,” “chemotherapy-induced anemia,” or “CIA”). All
articles that reported RBC transfusion rates stratified by
Hb level at DA initiation in patients with chemotherapy-
induced anemia were included, regardless of their study
designs. Risk differences in RBC transfusion rates at different
Hb stratification levels were calculated for the retrieved
studies.
The summary measure to be identified by the systematic
review was the risk difference in transfusion rates when DA
was initiated at higher versus lower Hb levels. This was
calculated [with 95 % confidence intervals (CI)] by sub-
tracting the transfusion rate at lower Hb levels from that at
higher levels.
Systematic literature review of economic studies
A second systematic literature review was performed to
identify articles that reported the cost of RBC transfusion.
Iterative searches were conducted using the PubMed data-
base for studies published between November 2000 and
November 2010. The following Medical Subject Heading
terms were included: “blood transfusion,” “autologous/eco-
nomics,” or “anemia/economics.” The reference lists of
retrieved studies from this review were scanned to identify
additional articles, with no date limitation set for reference
list reviewing. All articles that reported costs of RBC trans-
fusion were included, regardless of whether they were ret-
rospective or prospective, and whether transfusion was used
in oncology or other settings. To minimize potential bias
caused by differences among healthcare systems in different
geographic regions, studies reporting transfusion costs in
Europe were selected for further calculations.
Extracted data on costs of RBC transfusion for each
article were first converted to 2010 values using consumer
price index values for the relevant country [16–23]. Result-
ing cost was adjusted to Euro (€) values by using average
2010 currency exchange rates published by the European
Central Bank [24]. Average cost per 1 RBC unit was
calculated.
For studies using top-down (macro costing) method-
ology, unit cost was calculated by dividing the overall
cost by the total number of units transfused. In studies
using bottom-down (micro costing) methodology, each
resource component was identified and a unit cost cal-
culated. The overall cost of transfusion includes costs
associated with blood collection and processing, as well
as transfusion.
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Calculation of cost savings
To identify cost savings in the treatment of chemotherapy-
induced anemia associated with Hb level at the time of DA
initiation, the risk difference in RBC transfusion rates (based
on that identified in the systematic review of clinical stud-
ies) was multiplied by the identified average of RBC trans-
fusion cost in Europe (based on the systematic review of
economic studies). Among the retrieved clinical studies,
only one reported the actual number of units transfused
(3.5 units) [25], while 2 units have been reported as an
average number of units typically transfused [26, 27]. Cost
savings were, therefore, calculated based on transfusion of 2
and 3.5 units of RBC.
Results
Systematic literature review of clinical studies
The initial PubMed and conference abstract searches
revealed 500 potentially relevant articles, of which 27 full-
text articles and 4 abstracts were assessed further for eligi-
bility. Of these, eight publications were identified for inclu-
sion in the clinical literature review, including seven full-
text articles [25, 28–33] and one conference abstract (Fig. 1;
Table 1) [34]. Five publications were based on data from
clinical trials [29–31, 33, 34] and two reported results of
observational studies [25, 31], with one pooled analysis of
individual patient-level data from several clinical trials [32].
The eight independent studies used six different stratification
levels for Hb.
Impact of hemoglobin level at DA initiation on RBC trans-
fusion rate Despite the differences in baseline patient char-
acteristics, dose and regimen of DA, length of study, and
analytical techniques, all eight studies demonstrated a re-
duced need for RBC transfusion when DA was initiated at
higher versus lower Hb levels.
Three studies stratified Hb at the <10 versus ≥10 g/dl
level. In two, DAwas administered at 300 μg every 3 weeks
(Q3W) for 13 weeks [29] or 16 weeks [34], and transfusion
rates were reported between weeks 5 and 16. In the third
study, DA 200 μg was given Q2W for 24 weeks, and
transfusion rates were reported for months 1 and 6 [25].
The risk difference in transfusion rates ranged between 16 %
(95 % CI, 11–21 %) and 19 % (95 % CI, 10–28 %).
One study [30] stratified Hb at the ≤10 versus 10.5–12 g/dl
level.1 DA 300 μg was given Q3W for 22 weeks and the
transfusion incidence reported as the Kaplan–Meier percent-
age (K–M%) for weeks 1–13. The difference in risk of trans-
fusion was 17 % (95 % CI, 4–30 %) in favor of the higher Hb
level. Another study stratified Hb at the <9 versus ≥9 g/dl level
[32]. This was a 16-week prospective observational study
using DA 150 μg weekly with transfusion rates reported for
weeks 5–16. The risk difference for transfusion rates was 7 %
(95 % CI, −5–19 %) in favor of the higher Hb level.
St diAbstracts 
identified 
PubMed
128 
Conference 
abstracts
u es 
previously 
known to
and 
screened
records 371 
abstracts the authors
1 study
Total number of records assessed: 500 Records 
excluded
467
Number of full text Conference
Excluded
21 full text articlesAssessed 
for 
articles assessed for 
eligibility
abstracts and other 
sources
3 abstracts
(duplicate IV ironeligibility 27 full text article 5 abstracts 
1 full text article
, 
usage, transfusion 
rates reported but
not stratified)
7 full text articles
Number of 
studies
1 abstract*included in 
analysis
Fig. 1 Flow diagram of study
selection for clinical
studies. Asterisk two studies
identified by the literature
searches as conference abstracts
have since been published [22,
30] and are included here as full
text articles
1 Patients received DA immediately (Hb ≥10.5 g/dl) or waited until Hb
had decreased below 10 g/dl.
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Two studies used three stratification levels for Hb. The first
was a 15-week study with DA 500 μg Q3W in which Hb was
stratified at <9, 9 to <10, and ≥10 g/dl [33]. K–M% transfu-
sion rates were reported for weeks 1–15 and 5–15. The risk
differences for weeks 1–15 were 27% (95%CI, 16–38%) for
intermediate versus low Hb and 16 % (95 % CI, 9–23 %) for
higher versus intermediate Hb, with slightly lower risk differ-
ences when weeks 5–15 were analyzed [25 % (95 % CI, 14–
36%) and 13% (95% CI, 6–20%), respectively]. The second
studywas an observational study using DA 500μgQ3W, with
Hb stratified at <9, 9–10, and >10 g/dl [25]. The differences in
transfusion risk for weeks 1–12 were 31 % (95 % CI, 12–
50 %) for intermediate versus low Hb and 9 % (95 % CI, 1–
17 %) for higher versus intermediate Hb.
The final study, a pooled analysis of six studies with
various DA dosing regimens, used five Hb stratification
levels: <9, 9 to <10, 10 to <11, 11 to <12, and ≥12 g/dl
[32]. K–M% transfusion rates were reported for week 5
to weeks 12–18. Risk differences for the four compar-
isons were 10 % (95 % CI, 1–19 %), 12 % (95 % CI,
5–19 %), 7 % (95 % CI, 1–13 %), and 0 % (95 % CI,
–7 to 7 %), respectively.
Systematic literature review of economic studies
The initial PubMed searches revealed 286 potentially rele-
vant articles, of which 4 met the inclusion criteria. The
reference lists of these four articles were then analyzed and
additional articles identified, giving a total of 21 publica-
tions that met the inclusion criteria for the economic litera-
ture reviews, of which 8 were European (Fig. 2; Table 2)
[26, 27, 35–40]. One more study was identified at a later
stage [41]. There were three from the UK, one each from
Greece, Norway, Portugal, Spain, and Sweden, and one that
included costs from Switzerland and Austria. The studies
were conducted between 1998 and 2008, and all reported
the actual year of the study and the actual-year costs.
Three studies assessed the cost of transfusion in an on-
cology setting (one in a general oncology department, one in
a hemato-oncology department, and one in hematology and
oncology departments), two in a surgery setting, and three in
a general hospital setting, and one was a review. The costs
reported in our systematic review are all allogeneic transfu-
sion cost. The costs of transfusion were most frequently
assessed from the hospitals’ perspective (4/9 studies). Soci-
etal perspective was the approach in two studies, in which
indirect costs such as donor productivity loss, donor trans-
portation costs, and patient transportation costs were also
considered. One study took the healthcare provider’s per-
spective, and one took the payer’s perspective.
Cost of RBC transfusion The 2010-adjusted cost of 1 unit of
RBC transfusion in Europe ranged from €130 to €537 (Table 3),Ta
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with an average of €359. In general, the cost of transfusing a
second unit was slightly less expensive than the first because
blood grouping, Kell typing, and cross-matching of the patient
only need to be performed before the initial transfusion.
Impact of baseline Hb level on cost The risk difference in
transfusion rates (identified by systematic review of clinical
studies) was multiplied by the midpoint of the range of cost of
transfusion (identified by systematic review of economic
studies). Overall, the cost savings of initiating treatment with
DA at higher versus lower Hb levels ranged from €503 to
€2,226 (2 units transfused) and €880 to €3,895 (3.5 units
transfused) for every ten patients (Table 4). Decrease in trans-
fusion costs could offset the increase in DA costs.
Discussion
To the best of our knowledge, the present study is the first to
examine the impact of Hb level at DA initiation on the cost of
treating chemotherapy-induced anemia. The findings suggest
that RBC transfusion incidence decreases with higher Hb
levels at the time of DA initiation and that a reduction in
transfusion rate is associated with reduced costs, although
the actual cost savings varied between the studies examined.
Although we would have preferred to combine the studies in a
meta-analysis to provide more precise estimates, the hetero-
geneity of the studies in terms of their study designs and
reporting of transfusion rates stratified by Hb level made this
impossible. It should also be noted that the measurement
period of transfusion rates and the analytical method used to
report transfusion rates (Kaplan–Meier or raw percentages)
also varied between studies. As Kaplan–Meier estimates ac-
count for dropouts from the studies, risk differences calculated
from such estimates of transfusion rates are more likely to
reflect a population estimate, and cost savings calculated on
this basis are, therefore, more likely to reflect real-life clinical
practice.
While the present study showed that early initiation of
DA can lead to a reduction in the costs associated with RBC
transfusion, there are other important potential benefits from
reducing transfusion rates. For example, there are risks
Abstracts
identified and PubMed286 records
screened
Records assessed: 286 Records excluded:  277
Assessed for 
eligibility
Full text articles
assessed for eligibility: 9
Full text articles
excluded: 5
Additional 
Reference lists scanned: 
4 full text articles
screening and 
assessment of 
Articles identified from
reference lists
reference list scanning: 16
Articles previously known to 
the authors: 1
Total number of
potential studies
21 studies Non-European studies
excluded: 13
Number of 
8 studies
in analysis
studies included
Fig. 2 Flow diagram of study
selection for economic
studies
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associated with blood transfusions [1], and blood used for
transfusion is also a scarce resource that must be managed
efficiently. Thus, a reduction in transfusions may improve
the efficient allocation of scarce resources. Furthermore,
studies have shown that patients report a strong desire to
avoid transfusions [42]. While such outcomes are beyond
the scope of the present study, this preference can be mea-
sured using “willingness-to-pay” (WTP) analysis and can be
included in the calculation of cost savings. The purpose of
WTP measurements is to ascertain individual’s maximum
WTP for some—usually nonmarketed—good through hy-
pothetical survey questions [43]. Per the recommendation of
clinical guidelines, not only Hb levels but also patient
symptoms and circumstances should be considered when
deciding on the most appropriate treatment.
While effort should be made to reduce transfusion bur-
den, use of ESA should follow current clinical guideline and
label recommendations. Some years ago, several clinical
studies and meta-analyses suggested that ESAs may reduce
survival or increase disease progression [44–47]. More recent
studies and meta-analyses, however, have found no negative
impact upon survival [32, 48, 49]. Overall consensus has been
that, when used in accordance with the prescribing informa-
tion, ESA therapy is well tolerated, does not negatively affect
survival, and provides important clinical benefits for patients
with CIA by reducing the need for RBC transfusions and
exposure to associated risks [6–11].
Previously published cost-effectiveness analyses of ESAs
and RBC transfusions have generally been conducted on the
basis that ESAs are an alternative to RBC transfusion, and
have given conflicting results [50–52]. For example, Borget
et al. [52] and Borg et al. [51] both showed that use of an
ESA was cost-effective compared with RBC transfusion,
while Klarenbach et al. found that ESA use was not [50].
The validity of these studies in real-life practice is, however,
limited as guidelines state that ESAs and transfusions are
complementary, rather than mutually exclusive, in the man-
agement of chemotherapy-induced anemia [6].
Costs of transfusion varied between countries and also
from study to study, depending on the cost derivers included
in the analyses and the initial economic perspective taken.
While all direct labor and material costs incurred during the
three main phases of the transfusion process (collection
from the donor, preparation of the blood by running the
Table 2 Characteristics of the eight studies identified in the systematic review of economic studies
Study Study
year
Country Setting Study perspective Study design Type of costing Units
analyzed
Agrawal et al. 2006 [23] 2004 UK Hematology/oncology Hospital Prospective Bottom-up 2 units/1 unit
Glenngård et al. 2005 [24] 2002 Sweden General Societal Prospective Bottom-up 2 units/1 unit
Brilhante et al. 2008 [32] 2007 Portugal Hemato-oncology Hospital Prospective Bottom-up 2 units/1 unit
Darba et al. 2009 [33] 2002–2007 Spain Review Review Review Review 1 unit
Hadjianastassiou
et al. 2002 [34]
1998–1999 UK Surgery Hospital Retrospective Bottom-up 2 units/1 unit
Kanavos et al. 2006 [35] 2004 Greece General Societal Prospective Bottom-up 1 unit
Norum and Moen 2008 [36] 2005 Norway Oncology Payer Retrospective Top-down 1 unit
Varney and Guest 2003 [37] 2000–2001 UK General Healthcare provider Retrospective Top-down 1 unit
Shander 2010 2008 Switzerland
and Austria
Surgery Hospital Retrospective Top-down 1 unit
Table 3 2010 adjusted cost of
1 unit of red blood cell
transfusion in Europe
NOK Norwegian Krone, SEK
Swedish Krona
Study Cost of transfusion
(reported year)
2010 values in
original currencies
Adjusted 2010
values (€)
Agrawal et al. 2006 [23] £402 (2005) £460 €537
Glenngård et al. 2005 [24] SEK2,243 (2003) €249 SEK2,486 €261
Brilhante et al. 2008 [32] €349 (2007) €357 €357
Darba et al. 2009 [33] €350 (2007) €370 €370
Hadjianastassiou et al. 2002 [34] £90 (1999) £112 €130
Kanavos et al. 2006 [35] €355 (2004) €433 €433
Norum and Moen 2008 [36] NOK1,960 (2006) €240 NOK2,157 €269
Varney and Guest 2003 [37] £235 (2001) £286 €333
Shander 2010 $611.44 (2008) $613 €483
$522.45 $535 €421
Average cost €359
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necessary tests for safety, and transfusion to the recipient)
should have been considered when reporting costs, other
cost derivers are more dependent on the perspective taken.
The cost of DA treatment has been estimated at €2,094 in
Belgium [53] and ranged from €1,659 to €2,378 across
different European countries [54]. Considering differences
in the length of treatment (12–16 weeks in clinical trials and
6 weeks in DA cost analyses), the potential cost savings of
up to €3,895 for every ten patients demonstrated in the
present study could be used to treat approximately one
additional patient with DA. Decrease in transfusion costs
could offset the increase in DA costs.
Limitations of the present study include the potential for
publication selection bias arising from the use of a single
publication database (PubMed). For instance, retrieved
articles are highly dependent on the search strategy used,
and use of multiple sources may, therefore, have reduced
this effect [55]. The review of clinical studies found a trend
in transfusion reduction related to Hb level at DA initiation,
although it should be noted there were differences in base-
line patient characteristics, lengths of the studies, and ana-
lytical techniques used to report transfusion incidence. In
addition, it was assumed that the cost of RBC transfusion
was constant for the first and subsequent units. The costs for
the second unit of transfused blood, however, were found in
some of the cited studies to be slightly less expensive than
the first unit. The calculated cost savings reported here may,
therefore, slightly overestimate the actual cost savings in
clinical practice.
In conclusion, the findings of the clinical systematic
review showed that transfusion incidence increases when
DA is initiated at lower versus higher Hb levels. The cost of
transfusion was found to vary from country to country and
was dependent on the cost items included (e.g., direct and
indirect costs). Overall, this study shows that the Hb level at
DA initiation has a cost implication in the treatment of
chemotherapy-induced anemia: the lower the Hb level, the
greater the number of transfusions and the larger the overall
cost of treatment. In patients for whom DA treatment is
appropriate, treatment should, therefore, be initiated as early
as possible within guideline-defined Hb levels, to reduce the
need for transfusion and to decrease the overall cost of
treatment. Clinical circumstances and symptoms of the pa-
tient should be considered while deciding on the most
appropriate treatment of CIA.
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